Mounjaro vs Ozempic: Which GLP-1 Medication Is Right for You?
Mounjaro vs Ozempic: Which GLP-1 Medication Is Right for You?
Mounjaro (tirzepatide) and Ozempic (semaglutide) are two of the most prescribed medications for type 2 diabetes, and both are used off-label — or via weight-loss branded versions — for obesity. They are not the same drug, and the differences between them are clinically meaningful.
This guide compares them directly: mechanism of action, efficacy data, side effects, pricing, and the decision logic for choosing one over the other.
Important framing upfront: No direct head-to-head randomized controlled trial comparing Mounjaro and Ozempic has been published as of April 2026. Efficacy comparisons in this guide are drawn from indirect trial data (SURPASS vs SUSTAIN trial programs) and the single-arm SURMOUNT-5 trial. Treat all cross-drug comparisons as directional, not definitive.
Quick Comparison
| Mounjaro | Ozempic | |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Drug class | Dual GIP/GLP-1 agonist | GLP-1 agonist |
| Manufacturer | Eli Lilly | Novo Nordisk |
| FDA-approved for | Type 2 diabetes | Type 2 diabetes + CV risk reduction |
| Max dose | 15mg/week | 2.0mg/week |
| Injection frequency | Weekly | Weekly |
| A1C reduction (max dose) | ~2.3-2.6% | ~1.4-1.8% |
| Weight loss (trial data) | 12-22.5% (dose-dependent) | ~5-11% |
| Retail price (2026) | ~$1,069/mo | ~$936-1,100/mo |
| Weight-loss branded version | Zepbound | Wegovy |
| CV outcomes data | No approved indication (ongoing) | Yes — SELECT trial (MACE reduction) |
How They Work
Ozempic (Semaglutide) — GLP-1 Only
Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1 (GLP-1), an incretin hormone released by the gut after eating. By activating GLP-1 receptors, semaglutide:
- Suppresses appetite by signaling satiety to the hypothalamus
- Slows gastric emptying, prolonging fullness after meals
- Stimulates insulin secretion in a glucose-dependent manner
- Suppresses glucagon, reducing liver glucose output
Semaglutide was approved by the FDA for type 2 diabetes in 2017 (as Ozempic) and received an additional indication for cardiovascular risk reduction in adults with T2D and established cardiovascular disease based on the SELECT trial.
Mounjaro (Tirzepatide) — Dual GIP/GLP-1
Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first in its class. It activates two incretin receptors:
- GLP-1 receptor — same mechanism as semaglutide
- GIP receptor — glucose-dependent insulinotropic polypeptide receptor, which enhances insulin secretion, may promote fat oxidation, and appears to amplify weight-loss effects beyond GLP-1 alone
The GIP co-activation is the primary reason researchers believe tirzepatide produces greater weight loss. The exact contribution of GIP agonism to the clinical outcomes is still being studied — the mechanism is not fully characterized in humans.
What does the evidence show for Mounjaro vs Ozempic on A1C reduction?
For patients with type 2 diabetes, A1C reduction is often the primary clinical goal. Both drugs are highly effective — tirzepatide numerically outperforms semaglutide at comparable trial doses, but cross-trial comparisons have limitations.
From the SURPASS-2 Trial
SURPASS-2 (NEJM 2021) is the closest thing to an indirect comparison: it randomized patients with T2D to tirzepatide (5mg, 10mg, or 15mg) or semaglutide 1mg (the Ozempic dose at the time).
| Treatment | Mean A1C Reduction | Mean Weight Loss |
|---|---|---|
| Tirzepatide 5mg | −2.01% | −7.6 kg |
| Tirzepatide 10mg | −2.24% | −9.3 kg |
| Tirzepatide 15mg | −2.30% | −11.2 kg |
| Semaglutide 1mg | −1.86% | −5.7 kg |
Caveat: Ozempic is now available at 2mg, which was not the comparator in SURPASS-2. The 2mg dose of semaglutide shows greater A1C reduction (~1.4-1.8%) than the 1mg dose. The gap between tirzepatide and semaglutide at 2mg is narrower than the SURPASS-2 headline suggests.
What does the evidence show for Mounjaro vs Ozempic on weight loss?
Weight loss efficacy is where tirzepatide's advantage is most pronounced. Research consistently shows tirzepatide produces greater weight loss than semaglutide, though the magnitude of difference varies by dose and population.
Indirect Comparison (SURPASS vs SUSTAIN/STEP trials)
| Trial | Drug | Duration | Mean Weight Loss |
|---|---|---|---|
| SUSTAIN-1 (2017) | Ozempic 0.5mg | 30 weeks | ~3.7% |
| SUSTAIN-1 (2017) | Ozempic 1.0mg | 30 weeks | ~4.5% |
| STEP 2 (T2D, 2021) | Wegovy 2.4mg | 68 weeks | ~9.6% |
| SURPASS-1 (2021) | Tirzepatide 15mg | 40 weeks | ~14.8% |
| SURMOUNT-2 (T2D, 2023) | Tirzepatide 15mg | 72 weeks | 14.7% |
SURMOUNT-5 (Direct Comparative Signal, 2024)
SURMOUNT-5 compared tirzepatide 10mg/15mg against semaglutide 2.4mg (Wegovy dose) in adults with obesity or overweight. Results:
- Tirzepatide: 20.2% mean body weight reduction
- Semaglutide 2.4mg: 13.7% mean body weight reduction
- Difference: ~6.5 percentage points favoring tirzepatide
SURMOUNT-5 used the weight-loss branded doses (Zepbound vs Wegovy), not the diabetes doses (Mounjaro vs Ozempic). For patients using these drugs specifically for type 2 diabetes, the clinical picture remains informed primarily by SURPASS-2.
Side Effects
Both medications share a similar GI side effect profile, which is characteristic of the GLP-1 drug class.
Common (Both Drugs)
- Nausea (most common; typically peaks during dose escalation)
- Vomiting
- Diarrhea
- Constipation
- Decreased appetite
- Abdominal discomfort
Comparing Tolerability
Per SURPASS-2 trial data, GI adverse event rates were broadly similar between tirzepatide and semaglutide 1mg, though tirzepatide at higher doses showed slightly higher rates of nausea and vomiting. No head-to-head tolerability data exists comparing the two at equivalent weight-loss doses.
Individual tolerance varies significantly. Some patients who cannot tolerate semaglutide tolerate tirzepatide, and vice versa. Switching between drugs on clinical grounds is common.
Boxed Warning (Both Drugs)
Both Mounjaro and Ozempic carry an FDA boxed warning for medullary thyroid carcinoma (MTC). This warning is based on animal studies showing thyroid C-cell tumors in rodents at high doses. Whether this risk applies to humans is unknown; no increased incidence of MTC has been identified in clinical trials or post-market surveillance. Both drugs are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Other Notable Risks
- Pancreatitis: Cases reported post-market with both drugs; causal relationship not established
- Diabetic retinopathy: Rapid improvement in glycemic control may transiently worsen pre-existing retinopathy — monitor at initiation
- Heart rate: Both drugs increase mean heart rate; clinical significance unclear
- Gallbladder: Cholelithiasis and cholecystitis reported with both GLP-1 agents; weight loss is a contributing factor
How do Mounjaro and Ozempic compare on price?
Mounjaro lists at ~$1,069/mo and Ozempic at ~$936–$1,100/mo — but manufacturer savings programs and insurance substantially change what patients actually pay. For cash-pay patients focused on weight loss, Zepbound via LillyDirect at $299/mo is the most affordable tirzepatide option.
Retail Prices Without Insurance
| Drug | Retail Price/Month |
|---|---|
| Mounjaro (all doses) | ~$1,069 |
| Ozempic 0.5-2mg | ~$936–$1,100 |
With Manufacturer Savings Programs
- Mounjaro (Lilly): Lilly savings card can reduce out-of-pocket cost to ~$25/month with eligible commercial insurance. Without insurance, LillyDirect offers Zepbound (tirzepatide, obesity indication) starting at $299/month through self-pay.
- Ozempic (Novo Nordisk): NovoCare savings card reduces cost to ~$99/month with eligible commercial insurance. No equivalent self-pay cash program through Novo for Ozempic itself.
Weight-Loss Branded Versions (Cash-Pay)
If cost and weight loss are both priorities:
| Drug | Indication | Cash-Pay Program | Price |
|---|---|---|---|
| Zepbound (tirzepatide) | Obesity | LillyDirect | $299/mo |
| Wegovy (semaglutide 2.4mg) | Obesity | Varies by pharmacy | $299–$499/mo |
For patients without insurance coverage for GLP-1s, Zepbound through LillyDirect offers a lower entry price with tirzepatide's stronger efficacy profile.
Compounded Versions
Compounded tirzepatide and compounded semaglutide are available from 503B outsourcing facilities at $199–$349/month. However, the FDA has ended enforcement discretion for compounded semaglutide (shortage designation removed for Wegovy), and enforcement action for compounded tirzepatide has been initiated. Do not assume continued compounded availability. Discuss branded options with your prescriber and insurer.
Insurance Coverage
Type 2 Diabetes Indication
Both Mounjaro and Ozempic are covered by most commercial insurance plans for T2D with prior authorization. Step therapy (failing metformin first) is commonly required. Coverage is generally better for the T2D indication than obesity.
Obesity / Weight Loss Indication
Neither Mounjaro nor Ozempic is FDA-approved for obesity — their weight-loss branded equivalents (Zepbound, Wegovy) carry that indication. If you are prescribed Mounjaro or Ozempic for weight loss without T2D, prior authorization requirements are stricter, and some plans exclude coverage entirely.
Medicare: Neither drug is covered by Medicare Part D for weight loss. T2D indication has standard Part D coverage, but this excludes the obesity use case unless CMS policy changes.
Employer plans: Coverage of tirzepatide for obesity has expanded since SURMOUNT data was published. Check your plan's formulary directly — tirzepatide is being added by more employers than semaglutide at equivalent doses given the stronger efficacy data.
Which should you choose: Mounjaro or Ozempic?
| Clinical Situation | Preferred Choice | Reason |
|---|---|---|
| T2D + want maximum A1C reduction | Mounjaro (tirzepatide) | SURPASS-2 edge over semaglutide 1mg; likely edges 2mg as well |
| T2D + established CV disease | Ozempic (semaglutide) | SELECT trial: 20% reduction in MACE; no equivalent data for tirzepatide yet |
| Weight loss — cash-pay | Zepbound (tirzepatide) | $299/mo via LillyDirect; stronger efficacy signal |
| Weight loss — insurance coverage | Whichever is on formulary | Ask prescriber to check both; one may have better coverage |
| Previously tried semaglutide, poor response | Consider Mounjaro/Zepbound | Different mechanism (GIP co-agonism) may produce better response |
| GI intolerance on current GLP-1 | Try the other — tolerance is individual | No head-to-head tolerability data; clinical switching is common |
| Injection needle size preference | Both are similar | Weekly pen injection; identical dosing schedule |
| T2D + concurrent SGLT-2 inhibitor | Either; discuss with prescriber | Both can be used in combination |
Important: This table is a decision framework, not medical advice. Your prescriber will weigh your full clinical history, lab values, insurance plan, and contraindications before recommending a specific medication.
Frequently Asked Questions
Is Mounjaro better than Ozempic for weight loss? Indirect trial data and the SURMOUNT-5 trial suggest tirzepatide produces greater weight loss than semaglutide — approximately 6-8 percentage points more body weight reduction in comparable populations. However, no direct head-to-head RCT comparing Mounjaro and Ozempic specifically has been published. Research is ongoing. Tirzepatide's advantage is consistent across trials, but individual response varies.
Can I switch from Ozempic to Mounjaro? Yes. Switching between GLP-1 medications is common when one is not tolerated or not producing adequate response. The switch typically involves starting tirzepatide at the lowest dose (2.5mg) regardless of your current semaglutide dose. Your prescriber will guide the transition — do not self-switch without medical supervision.
Are Mounjaro and Ozempic approved for weight loss? No. Mounjaro is FDA-approved for type 2 diabetes. Ozempic is FDA-approved for type 2 diabetes and cardiovascular risk reduction. The weight-loss branded versions are Zepbound (tirzepatide) and Wegovy (semaglutide). Prescribing Mounjaro or Ozempic for obesity represents off-label use, which is legal and common but has insurance implications.
Does Ozempic have cardiovascular outcome data that Mounjaro doesn't? Yes. Ozempic's label includes a cardiovascular risk reduction indication based on the SELECT trial, which showed a 20% reduction in major adverse cardiovascular events (MACE) in adults with obesity or overweight and established cardiovascular disease. Tirzepatide has no equivalent approved indication as of April 2026, though cardiovascular outcome trials are underway.
Is the compounded version of either drug safe to use? The FDA has moved to restrict compounded semaglutide and tirzepatide as drug shortages have been resolved. Compounded versions lack the clinical trial data and manufacturing oversight of branded drugs. If you are currently using a compounded version, discuss transitioning to a branded option with your prescriber. Do not assume compound availability will continue.
Why does Mounjaro cost more if Zepbound is $299/month through LillyDirect? The $299/month LillyDirect price applies to Zepbound (tirzepatide with the obesity indication), not Mounjaro (tirzepatide with the T2D indication). The two products contain the same molecule at the same doses but have different regulatory approvals and access programs. Patients using Mounjaro for T2D access savings through the commercial Lilly card (~$25/month with insurance) rather than LillyDirect.
Which drug has fewer side effects? Both share a similar GI side effect profile (nausea, vomiting, diarrhea, constipation). Per trial data, Mounjaro at high doses showed marginally higher GI event rates than Ozempic 1mg. At equivalent weight-loss doses, no head-to-head tolerability comparison exists. Individual response is highly variable — some patients tolerate one drug but not the other.
Is Mounjaro or Ozempic worth it without insurance? At retail prices ($1,069 vs ~$936–$1,100/mo), neither is practical without insurance or savings programs. For cash-pay patients, the real comparison is Zepbound ($299/mo via LillyDirect) vs. compounded semaglutide ($149–$199/mo through telehealth platforms) — or orforglipron at $149/mo once approved.
What is the bottom line on Mounjaro vs Ozempic?
Mounjaro (tirzepatide) and Ozempic (semaglutide) are both effective, well-studied GLP-1-class medications with different mechanisms and different clinical strengths. Tirzepatide's dual GIP/GLP-1 mechanism produces greater weight loss across trial data. Semaglutide has a cardiovascular risk reduction indication that tirzepatide does not yet have.
The best choice depends on your clinical profile, insurance coverage, and treatment goals. If cardiovascular outcomes are a priority, Ozempic's SELECT data matters. If weight loss is the primary driver and you're paying out-of-pocket, Zepbound's LillyDirect price and tirzepatide's efficacy signal both point in the same direction.
Talk to a prescriber who can review your full history — both drugs are prescription-only.
Related Comparisons
- Mounjaro vs Wegovy — head-to-head SURMOUNT-5 weight loss data
- Mounjaro vs Zepbound — same molecule, different indications
- Ozempic vs Wegovy — semaglutide for diabetes vs weight loss
- Tirzepatide Side Effects Guide
- Ro GLP-1 Provider Review
- Mounjaro Cost Without Insurance 2026
Pricing reflects publicly available information as of April 2026 and is subject to change. This content is for informational purposes only and does not constitute medical advice.
Where to Get These Medications
Compare providers offering GLP-1 medications.
Related Guides
Does Medicare Cover Ozempic? What You Need to Know in 2026
Does Medicare cover Ozempic in 2026? Yes for diabetes, no for weight loss. Learn about Part D coverage rules, costs, prior authorization, and cheaper alternatives.
Read guide →Generic Ozempic & Semaglutide: Timeline, Patents, and What to Expect
When will generic semaglutide (Ozempic) be available in the US? Patent landscape, international generics at $3/month, biosimilar timeline, and what you can do now to save.
Read guide →How Long Does Ozempic Take to Work? (Wegovy & Tirzepatide Too)
Ozempic and Wegovy typically suppress appetite within 1–2 weeks of starting. Meaningful weight loss appears around weeks 4–8. Full results at the highest dose take 12–16+ months. Here is the precise timeline, and what to do if nothing is happening.
Read guide →How to Get Ozempic Online in 2026: Step-by-Step Guide
Step-by-step guide to getting semaglutide online in 2026 — eligibility, telehealth providers, pricing, brand vs compounded, Hims brand-only status, orforglipron option, and red flags to avoid.
Read guide →